New tumor lysis syndrome data have been reported by researchers at University of Tsukuba
2009 AUG 3 - (NewsRx.com) -- "Tumor lysis syndrome (TLS) is rare in the treatment of solid tumors, but it may occur in myelolymphoproliferative diseases. A 58-year-old man with bulky metastatic melanoma of the liver was treated with transcatheter arterial infusion of cisplatin and embolization therapy," scientists writing in the International Journal of Dermatology report. "The patient developed classic signs of TLS within 24 h of chemotherapy, including acute renal failure. The patient was treated with aggressive hydration, allopurinol, and repeated hemodialysis. He gradually improved and his biochemical markers returned to normal. TLS is an uncommon, but potentially life-threatening, complication in melanoma and other solid tumors," wrote Y. Nakamura and colleagues, University of Tsukuba. The researchers concluded: "It is important for oncologists to recognize this complication and prevent its development if bulky metastatic disease and several pre-existing risk factors, such as multiple and bulky liver metastases, elevated lactate dehydrogenase, and hyperuricemia, are present.." Nakamura and colleagues published their study in International Journal of Dermatology (Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma. International Journal of Dermatology, 2009;48(7):763-767). Additional information can be obtained by contacting Y. Nakamura, University of Tsukuba, Graduate School Comprehensive Human Science, Dept. of Dermatology, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan. The publisher of the International Journal of Dermatology can be contacted at: Wiley-Blackwell Publishing, Inc., Commerce Place, 350 Main St., Malden 02148, MA, USA. Keywords: Japan, Tsukuba, Acute Kidney Failure, Acute Renal Failure, Allopurinol, Angiology, Chemotherapy, Cisplatin, Dermatology, Drug Therapy, Drugs, Embolization, Kidney, Melanoma, Nephrology, Oncology, Pharmaceuticals, Renal Failure, Solid Cancers, Solid Carcinomas, Treatment, Tumor Lysis Syndrome, University of Tsukuba. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
